- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT02965807
Effect of Bronchial Thermoplasty on Moderate Bronchial Asthma in China
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
This is a multi-center, open-label and single arm study. At least 50 patients with moderate asthma receive Bronchial Thermoplasty for three times. Asthma Quality of Life Questionnaire (AQLQ), Asthma Control Questionnaire (ACQ), Frequency of mild asthma acute attack, PEF, FEV1, Emergency and Hospitalization are compared between before and after BT treatment.
The unified peak flow test meter will be provided to all subjects enrolled in this study. They will get a follow-up diary book before leaving hospital. In order to ensure the efficiency, all enrolled asthma patients are trained and tested by doctors and nurses from in-patient or out-patient department when they follow up, including how to use the PEF meter, how to read and record the data. As for the dosage of medication, all the medication uses are followed the doctor's advice, once the rescue medications were used, the times and dosages are mandatory to be recorded in the diary book by the patients themselves.
Studientyp
Einschreibung (Voraussichtlich)
Phase
- Phase 2
- Phase 1
Kontakte und Standorte
Studienorte
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510000
- Rekrutierung
- Guangzhou Institute of Respiratory Disease
-
Kontakt:
- yanqiuzi cheng
- Telefonnummer: 15915709477
- E-Mail: 736145682@qq.com
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- age between 18y and 65y.
- no improvement after ICS and LABA treatment in patients with moderate asthma
- have not received BT before
- stable more than 6 weeks before enrolled in this study
- no implantable electrical device (e.g. cardiac pacemaker)
- no permanent anticoagulant is being used
Exclusion Criteria:
- Smoking and have obvious emphysema
- Chest CT showed lower lobe bronchial stenosis or distal complete atelectasis
- FEV1 < 65% predicted value after using bronchodilator
- airway infection(within 6 weeks)
- any circumstances as the following within the past 1 year: lower respiratory tract infection (LRTI) for 4 times or above; hospitalization due to respiratory diseases for more than 3 times; increase the dosage of oral corticosteroids due to asthma exacerbation for more than 4 times
- received endotracheal intubation or ICU admission due to asthma attack within the past 2 years
- concomitant allergic bronchopulmonary aspergillosis
- Implantable electronic devices (such as cardiac pacemaker)/NYHA class IV and/or acute myocardial infarction within the past 3 months
- coagulation disorders,cannot stop taking anticoagulant、antiplatelet drugs or nonsteroidal anti-inflammatory drugs
- increasing the risk of adverse reactions during bronchoscopy or anesthesia as the followings: pregnancy, insulin-dependent diabetes, epilepsy, or the other severe complications, such as uncontrolled coronary heart disease, acute or chronic renal failure or uncontrolled hypertension
- others:vocal cord dysfunction、chronic nasosinusitis、airway obstruction or uncontrolled obstructive sleep apnea syndrome
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: N / A
- Interventionsmodell: Einzelgruppenzuweisung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Experimental: Bronchial Thermoplasty
Moderate bronchial asthma patients under the Bronchial Thermoplasty.
|
patients will be under Bronchial Thermoplasty approximately every three weeks.And totally having three surgerys will be considered as completed.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
change from baseline2 AQLQ score after Bronchial Thermoplasty
Zeitfenster: baseline2、6 weeks after the third surgery、3、6、9 、12 months after the third surgery and stoping laba for 2 weeks
|
baseline2、6 weeks after the third surgery、3、6、9 、12 months after the third surgery and stoping laba for 2 weeks
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
---|---|---|
decline from baseline 2 in the ACQ score for 0.5 or more
Zeitfenster: baseline2、6 weeks after the third surgery、3、6、9 、12 months after the third surgery and stoping laba for 2 weeks
|
baseline2、6 weeks after the third surgery、3、6、9 、12 months after the third surgery and stoping laba for 2 weeks
|
|
Frequency of mild asthma acute execration after Bronchial Thermoplasty
Zeitfenster: baseline2、6 weeks after the third surgery、3、6、9 、12 months after the third surgery and stoping laba for 2 weeks
|
A mild exacerbation is defined as 2 consecutive days when at least one of the following occurs:1. Morning peak expiratory flow falls at least 20% below the average morning peak flow recorded at the baseline (the first 2 weeks during the 4-week baseline period). 2. More than 3 more puffs of rescue short acting bronchodilator are required than the average usage at the baseline(the first 2 weeks during the 4-week baseline period). 3. Awakening at night with asthma symptoms. |
baseline2、6 weeks after the third surgery、3、6、9 、12 months after the third surgery and stoping laba for 2 weeks
|
change from baseline2 peak flow after Bronchial Thermoplasty
Zeitfenster: baseline2、6 weeks after the third surgery、3、6、9 、12 months after the third surgery and stoping laba for 2 weeks
|
baseline2、6 weeks after the third surgery、3、6、9 、12 months after the third surgery and stoping laba for 2 weeks
|
|
change from baseline2 FEV1 after Bronchial Thermoplasty
Zeitfenster: baseline2、6 weeks after the third surgery、3、6、9 、12 months after the third surgery and stoping laba for 2 weeks
|
baseline2、6 weeks after the third surgery、3、6、9 、12 months after the third surgery and stoping laba for 2 weeks
|
|
change from baseline2 FEV1/FVC after Bronchial Thermoplasty
Zeitfenster: baseline2、6 weeks after the third surgery、3、6、9 、12 months after the third surgery and stoping laba for 2 weeks
|
baseline2、6 weeks after the third surgery、3、6、9 、12 months after the third surgery and stoping laba for 2 weeks
|
|
change from baseline2 FEV1 predicted after Bronchial Thermoplasty
Zeitfenster: baseline2、6 weeks after the third surgery、3、6、9 、12 months after the third surgery and stoping laba for 2 weeks
|
baseline2、6 weeks after the third surgery、3、6、9 、12 months after the third surgery and stoping laba for 2 weeks
|
|
the percentage of Emergency
Zeitfenster: baseline2、6 weeks after the third surgery、3、6、9 、12 months after the third surgery and stoping laba for 2 weeks
|
baseline2、6 weeks after the third surgery、3、6、9 、12 months after the third surgery and stoping laba for 2 weeks
|
|
Hospitalization and Asymptomatic days
Zeitfenster: baseline2、6 weeks after the third surgery、3、6、9 、12 months after the third surgery and stoping laba for 2 weeks
|
baseline2、6 weeks after the third surgery、3、6、9 、12 months after the third surgery and stoping laba for 2 weeks
|
|
the incidence of severe respiratory adverse events
Zeitfenster: baseline2、6 weeks after the third surgery、3、6、9 、12 months after the third surgery and stoping laba for 2 weeks
|
baseline2、6 weeks after the third surgery、3、6、9 、12 months after the third surgery and stoping laba for 2 weeks
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: shiyue li, director, Guangzhou Institute of Respiratory Disease
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Solway J, Irvin CG. Airway smooth muscle as a target for asthma therapy. N Engl J Med. 2007 Mar 29;356(13):1367-9. doi: 10.1056/NEJMe078005. No abstract available.
- Danek CJ, Lombard CM, Dungworth DL, Cox PG, Miller JD, Biggs MJ, Keast TM, Loomas BE, Wizeman WJ, Hogg JC, Leff AR. Reduction in airway hyperresponsiveness to methacholine by the application of RF energy in dogs. J Appl Physiol (1985). 2004 Nov;97(5):1946-53. doi: 10.1152/japplphysiol.01282.2003. Epub 2004 Jul 16.
- Lai CK, De Guia TS, Kim YY, Kuo SH, Mukhopadhyay A, Soriano JB, Trung PL, Zhong NS, Zainudin N, Zainudin BM; Asthma Insights and Reality in Asia-Pacific Steering Committee. Asthma control in the Asia-Pacific region: the Asthma Insights and Reality in Asia-Pacific Study. J Allergy Clin Immunol. 2003 Feb;111(2):263-8. doi: 10.1067/mai.2003.30.
- Miller JD, Cox G, Vincic L, Lombard CM, Loomas BE, Danek CJ. A prospective feasibility study of bronchial thermoplasty in the human airway. Chest. 2005 Jun;127(6):1999-2006. doi: 10.1378/chest.127.6.1999.
- Cox G, Thomson NC, Rubin AS, Niven RM, Corris PA, Siersted HC, Olivenstein R, Pavord ID, McCormack D, Chaudhuri R, Miller JD, Laviolette M; AIR Trial Study Group. Asthma control during the year after bronchial thermoplasty. N Engl J Med. 2007 Mar 29;356(13):1327-37. doi: 10.1056/NEJMoa064707.
- Pavord ID, Cox G, Thomson NC, Rubin AS, Corris PA, Niven RM, Chung KF, Laviolette M; RISA Trial Study Group. Safety and efficacy of bronchial thermoplasty in symptomatic, severe asthma. Am J Respir Crit Care Med. 2007 Dec 15;176(12):1185-91. doi: 10.1164/rccm.200704-571OC. Epub 2007 Sep 27.
- Castro M, Rubin A, Laviolette M, Hanania NA, Armstrong B, Cox G; AIR2 Trial Study Group. Persistence of effectiveness of bronchial thermoplasty in patients with severe asthma. Ann Allergy Asthma Immunol. 2011 Jul;107(1):65-70. doi: 10.1016/j.anai.2011.03.005. Epub 2011 Apr 14.
- Cox G, Miller JD, McWilliams A, Fitzgerald JM, Lam S. Bronchial thermoplasty for asthma. Am J Respir Crit Care Med. 2006 May 1;173(9):965-9. doi: 10.1164/rccm.200507-1162OC. Epub 2006 Feb 2.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Voraussichtlich)
Studienabschluss (Voraussichtlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2015-17
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Mittelschweres Asthma
-
CinnagenAbgeschlossenAllergisches Asthma | Unkontrolliert Moderat bis SchwerIran, Islamische Republik
-
Daiichi Sankyo, Inc.AbgeschlossenEine Studie zur Quizartinib-Pharmakokinetik bei Teilnehmern mit mittelschwerer LeberfunktionsstörungLeberfunktionsstörung | Moderat eingeschränkte LeberfunktionVereinigte Staaten
-
AstraZenecaJohnson & JohnsonAbgeschlossenFür eine diagnostische gastrointestinale Endoskopie und gastrointestinale endoskopische Polypektomie muss die Sedierung moderat seinJapan
-
Souzy KamalAbgeschlossenParodontitis chronisch generalisiert moderatÄgypten
-
Plovdiv Medical UniversityAbgeschlossenChronische Parodontitis, generalisiert, moderat
-
Assiut UniversityUnbekanntCannabiskonsumstörung, moderat
-
Monash UniversityTurning PointAbgeschlossenCannabiskonsumstörung, moderat | Cannabiskonsumstörung, schwerAustralien
-
Oregon Research InstituteAbgeschlossenCannabiskonsumstörung, leicht | Cannabiskonsumstörung, moderatVereinigte Staaten
-
McMaster UniversityCenter for Medicinal Cannabis ResearchNoch keine RekrutierungCannabiskonsumstörung, moderat | Cannabiskonsumstörung, schwer
-
Lyndra Inc.National Institute on Drug Abuse (NIDA)ZurückgezogenOpioidkonsumstörung, moderat
Klinische Studien zur Bronchial Thermoplasty
-
Centre Hospitalier Universitaire de Saint EtienneMinistry of Health, France; Ligue contre le cancer, FranceBeendetKarzinom, nicht-kleinzellige Lunge | LungentumorFrankreich
-
Necmettin Erbakan UniversityAbgeschlossenBrustkrebs | Chemotherapie-Effekt | Periphere NeuropathienTruthahn
-
University of British ColumbiaMinistry of Health, Zambia; UNICEF; Tropical Disease Research CentreAbgeschlossen
-
Hannover Medical SchoolELLA-CS, Czech RepublicAbgeschlossen
-
Clyde MatavaZurückgezogen
-
Society for Applied StudiesWorld Health Organization; Christian Medical College, Vellore, India; ArthAbgeschlossenUnkomplizierte schwere akute MangelernährungIndien
-
H. Lundbeck A/SAlder Biopharmaceuticals, Inc.Abgeschlossen
-
Hoffmann-La RocheAbgeschlossenPostmenopausale OsteoporoseVereinigte Staaten
-
George Washington UniversityNational Institute on Minority Health and Health Disparities (NIMHD); Shenandoah... und andere MitarbeiterZurückgezogenThrombose; ArterieVereinigte Staaten
-
Actavis Mid-Atlantic LLCAbgeschlossen